BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 29024412)

  • 1. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation.
    Han S; Lee S; Yang JD; Leise MD; Ahn JH; Kim S; Jung K; Gwak MS; Kim GS; Ko JS
    Liver Transpl; 2018 Jan; 24(1):44-55. PubMed ID: 29024412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Bilirubin Levels of Healthy Living Liver Donors Are Associated With Lower Posttransplant Hepatocellular Carcinoma Recurrence.
    Han S; Yang JD; Sinn DH; Ko JS; Kim JM; Shin JC; Son HJ; Gwak MS; Joh JW; Kim GS
    Transplantation; 2016 Sep; 100(9):1933-8. PubMed ID: 27362316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors.
    Han S; Yang JD; Sinn DH; Kim JM; Choi GS; Jung G; Ahn JH; Kim S; Ko JS; Gwak MS; Kwon CHD; Leise MD; Gwak GY; Heimbach JK; Kim GS
    Ann Surg; 2018 Dec; 268(6):1043-1050. PubMed ID: 28628564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.
    Pang Q; Zhang JY; Xu XS; Song SD; Qu K; Chen W; Zhou YY; Miao RC; Liu SS; Dong YF; Liu C
    World J Gastroenterol; 2015 May; 21(18):5607-21. PubMed ID: 25987786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond milan criteria.
    Lee EC; Kim SH; Shim JR; Park SJ
    Liver Transpl; 2018 Jan; 24(1):35-43. PubMed ID: 28885774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
    Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
    Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
    Kim YR; Park S; Han S; Ahn JH; Kim S; Sinn DH; Jeong WK; Ko JS; Gwak MS; Kim GS
    Sci Rep; 2018 May; 8(1):7157. PubMed ID: 29740069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
    Yoon YI; Song GW; Lee SG; Hwang S; Kim KH; Kim SH; Kang WH; Cho HD; Jwa EK; Kwon JH; Tak EY; Kirchner VA
    J Hepatol; 2018 Jun; 68(6):1153-1162. PubMed ID: 29452208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in the Risk of Posttransplant Hepatocellular Carcinoma Recurrence After the Conversion to Prestorage Leukoreduction for Transfused Red Blood Cells.
    Kwon JH; Han S; Jang JS; Lee KW; Ahn JH; Kim K; Jeon S; Gwak MS; Ko JS; Kim GS; Joh JW; Cho D
    Transplantation; 2021 Mar; 105(3):577-585. PubMed ID: 32265418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living donor liver transplantation for hepatocellular carcinoma.
    Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
    Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
    Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.
    Halazun KJ; Najjar M; Abdelmessih RM; Samstein B; Griesemer AD; Guarrera JV; Kato T; Verna EC; Emond JC; Brown RS
    Ann Surg; 2017 Mar; 265(3):557-564. PubMed ID: 27611615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
    Lee EC; Kim SH; Lee SD; Park H; Lee SA; Park SJ
    World J Gastroenterol; 2016 Apr; 22(14):3803-12. PubMed ID: 27076765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.